Related references
Note: Only part of the references are listed.ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680+chemotherapy plus zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).
Gulam Abbas Manji et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Role of Hypoxia-Mediated Autophagy in Tumor Cell Death and Survival
Rania F. Zaarour et al.
CANCERS (2021)
HIF-1a expression and differential effects on survival in patients with oral cavity, larynx, and oropharynx squamous cell carcinomas
Justin E. Swartz et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2021)
CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway
Jinglian Tao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration
Alexandra Giatromanolaki et al.
BRITISH JOURNAL OF CANCER (2020)
Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
Sevda Jafari et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
CTLA-4: From mechanism to autoimmune therapy
Arezoo Hosseini et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy
Jeffrey C. Thompson et al.
LUNG CANCER (2020)
Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
Guojun Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Combining microenvironment normalization strategies to improve cancer immunotherapy
Fotios Mpekris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients
Esraa A. Salama et al.
FRONTIERS IN ONCOLOGY (2020)
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
Hirofumi Ohmura et al.
BRITISH JOURNAL OF CANCER (2020)
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
Linlin Ma et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra Van Wilpe et al.
ONCOIMMUNOLOGY (2020)
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
Alyssa Vito et al.
CELLS (2020)
Photodynamic Therapy and Immune Checkpoint Blockade†
Gwendolyn M. Cramer et al.
PHOTOCHEMISTRY AND PHOTOBIOLOGY (2020)
Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways
Yi-Na Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)
Shiyi Liu et al.
CANCER CELL INTERNATIONAL (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer
Qinchuan Wu et al.
HEPATOLOGY (2019)
Fecal bacteria from ulcerative colitis patients downregulate Tim-3-mediated inhibitory effects on monocytes in vitro
Shaoxuan Wang et al.
MICROBIAL PATHOGENESIS (2019)
Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift
Jung Eun Park et al.
ONCOGENE (2019)
Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
Saeed Daneshmandi et al.
CANCERS (2019)
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
Audrey Lequeux et al.
CANCER LETTERS (2019)
Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells
Xiteng Yin et al.
CELLULAR ONCOLOGY (2019)
Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma
Rina Nakajima et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2019)
Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome
Rong Fu et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2019)
Immuno-oncology drug development goes global
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Vascular regulation of antitumor immunity
Lance L. Munn et al.
SCIENCE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Hypoxia-induced HIF-1α and ZEB1 are critical for the malignant transformation of ameloblastoma via TGF-β-dependent EMT
Shohei Yoshimoto et al.
CANCER MEDICINE (2019)
PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
Jiaqiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
SENP1-mediated deSUMOylation of USP28 regulated HIF-1 accumulation and activation during hypoxia response
Shi-chun Du et al.
CANCER CELL INTERNATIONAL (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Engineering therapeutic bispecific antibodies using CrossMab technology
Christian Klein et al.
METHODS (2019)
A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors
Andrea M. Chambers et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2019)
Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
Franziska Eckert et al.
FRONTIERS IN IMMUNOLOGY (2019)
Adaptation of Operational Parameters of Cold Atmospheric Plasma for in Vitro Treatment of Cancer Cells
Eda Gjika et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Targeting tumor-associated acidity in cancer immunotherapy
Ruben Lacroix et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma
Xinfeng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
Jian-Feng Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression
Jorgen Kjaergaard et al.
JOURNAL OF IMMUNOLOGY (2018)
Reciprocal loop of hypoxia-inducible factor-1α (HIF-1α) and metastasis-associated protein 2 (MTA2) contributes to the progression of pancreatic carcinoma by suppressing E-cadherin transcription
Shuai Zhu et al.
JOURNAL OF PATHOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways
Xiaofan Guo et al.
ONCOGENE (2018)
Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Joel P. Joseph et al.
ORAL ONCOLOGY (2018)
Association of PD-L1 and HIF-1 alpha Coexpression with Poor Prognosis in Hepatocellular Carcinoma
Xiaomeng Dai et al.
TRANSLATIONAL ONCOLOGY (2018)
MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect
Zhiqiang Chen et al.
CELL DEATH & DISEASE (2018)
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37
Dhifaf Sarhan et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3
Yue Xing et al.
PHARMACOLOGICAL RESEARCH (2018)
LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response
Inna Serganova et al.
PLOS ONE (2018)
Hypoxic Microenvironment and Metastatic Bone Disease
Toru Hiraga
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Unravelling the Interplay between Extracellular Acidosis and Immune Cells
Fernando Erra Diaz et al.
MEDIATORS OF INFLAMMATION (2018)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells
J. Feng et al.
ONCOGENE (2017)
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Francois Bertucci et al.
CURRENT ONCOLOGY REPORTS (2017)
TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis
Yang Zhang et al.
ONCOTARGET (2017)
Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
Eva M. Palsson-McDermott et al.
FRONTIERS IN IMMUNOLOGY (2017)
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Stephane Terry et al.
FRONTIERS IN IMMUNOLOGY (2017)
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2017)
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma The ARISER Randomized Clinical Trial
Karim Chamie et al.
JAMA ONCOLOGY (2017)
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Asis Palazon et al.
CANCER CELL (2017)
Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity
Pankaj Seth et al.
CANCER RESEARCH (2017)
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives
Matthew S. Farina et al.
DRUGS (2017)
Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy
Xianda Zhao et al.
CANCER RESEARCH (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
HIF-1 at the crossroads of hypoxia, inflammation, and cancer
Kuppusamy Balamurugan
INTERNATIONAL JOURNAL OF CANCER (2016)
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
A. Murtaza et al.
EUROPEAN JOURNAL OF CANCER (2016)
Suppression of the expression of hypoxia-inducible factor-1α by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats
Ying Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
Min-Sun Jin et al.
VIRCHOWS ARCHIV (2016)
Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy
Beom-Ju Hong et al.
RADIATION ONCOLOGY JOURNAL (2016)
Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy
Robert D. Leone et al.
CANCER CELL (2015)
Immunogenic cell death
Abhishek D. Garg et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2015)
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Binh L. Phong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Stephen M. Hatfield et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer
Wenjing Zhang et al.
PLOS ONE (2015)
Photodynamic Therapy and Its Role in Combined Modality Anticancer Treatment
N. Patrik Brodin et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2015)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis
Lei Qin et al.
IMMUNOTHERAPY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Hypoxia-Induced Snail Expression Through Transcriptional Regulation by HIF-1α in Pancreatic Cancer Cells
Guang-hui Zhu et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
Andrew L. Doedens et al.
NATURE IMMUNOLOGY (2013)
The Critical Impact of HIF-1a on Gastric Cancer Biology
Yoshihiko Kitajima et al.
Cancers (2013)
Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape
Francois Ghiringhelli et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells
Michael R. Olin et al.
CANCER RESEARCH (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Direct regulation of TWIST by HIF-1α promotes metastasis
Muh-Hwa Yang et al.
NATURE CELL BIOLOGY (2008)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Share Paper
